Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Short-term Investments (2021 - 2025)

Historic Short-term Investments for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $338.5 million.

  • Krystal Biotech's Short-term Investments rose 5789.71% to $338.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $338.5 million, marking a year-over-year increase of 5789.71%. This contributed to the annual value of $252.7 million for FY2024, which is 4532.76% up from last year.
  • According to the latest figures from Q3 2025, Krystal Biotech's Short-term Investments is $338.5 million, which was up 5789.71% from $328.2 million recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Short-term Investments ranged from a high of $338.5 million in Q3 2025 and a low of $1.2 million during Q1 2021
  • Its 5-year average for Short-term Investments is $189.4 million, with a median of $206.8 million in 2022.
  • As far as peak fluctuations go, Krystal Biotech's Short-term Investments skyrocketed by 1314751.6% in 2022, and later crashed by 1998.47% in 2023.
  • Krystal Biotech's Short-term Investments (Quarter) stood at $96.8 million in 2021, then soared by 124.34% to $217.3 million in 2022, then decreased by 19.98% to $173.8 million in 2023, then soared by 45.33% to $252.7 million in 2024, then soared by 33.96% to $338.5 million in 2025.
  • Its Short-term Investments stands at $338.5 million for Q3 2025, versus $328.2 million for Q2 2025 and $308.1 million for Q1 2025.